@prefix : <http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitis> .
@prefix dc: <http://purl.org/dc/elements/1.1/> .
@prefix mp: <http://purl.org/mp/> .
@prefix oa: <http://www.w3.org/ns/oa#> .
@prefix obo: <http://purl.obolibrary.org/obo/> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix xml: <http://www.w3.org/XML/1998/namespace> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix core: <http://purl.obolibrary.org/obo/uberon/core#> .
@prefix foaf: <http://xmlns.com/foaf/0.1/> .
@prefix pato: <http://purl.obolibrary.org/obo/pato#> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix skos: <http://www.w3.org/2004/02/skos/core#> .
@prefix time: <http://www.w3.org/2006/time#> .
@prefix core1: <http://purl.obolibrary.org/obo/core#> .
@prefix terms: <http://purl.org/dc/terms/> .
@prefix uberon: <http://purl.obolibrary.org/obo/uberon#> .
@prefix subsets: <http://purl.obolibrary.org/obo/ro/subsets#> .
@prefix oboInOwl: <http://www.geneontology.org/formats/oboInOwl#> .
@prefix OpenPVSignal: <http://purl.org/OpenPVSignal/OpenPVSignal.owl#> .
@base <http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitis> .

<http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitis> rdf:type owl:Ontology ;
                                                                      owl:imports <http://purl.org/OpenPVSignal/OpenPVSignal.owl> ,
                                                                                  mp: ;
                                                                      rdfs:isDefinedBy "https://apps.who.int/iris/handle/10665/255514/"^^xsd:anyURI ;
                                                                      rdfs:label "Ustekinumab and Vasculitis"^^xsd:Literal ;
                                                                      owl:versionInfo "draft-v0.95-20211112"@en .

#################################################################
#    Annotation properties
#################################################################

###  http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code
OpenPVSignal:has_ATC_code rdf:type owl:AnnotationProperty .


###  http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code
OpenPVSignal:has_ICD_code rdf:type owl:AnnotationProperty .


###  http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code
OpenPVSignal:has_MedDRA_code rdf:type owl:AnnotationProperty .


###  http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term
OpenPVSignal:has_MedDRA_prefered_term rdf:type owl:AnnotationProperty .


###  http://purl.org/dc/elements/1.1/publisher
dc:publisher rdf:type owl:AnnotationProperty .


###  http://purl.org/dc/terms/hasVersion
terms:hasVersion rdf:type owl:AnnotationProperty .


###  http://www.w3.org/2004/02/skos/core#exactMatch
skos:exactMatch rdf:type owl:AnnotationProperty .


###  http://www.w3.org/2004/02/skos/core#inScheme
skos:inScheme rdf:type owl:AnnotationProperty .


###  http://www.w3.org/2004/02/skos/core#notation
skos:notation rdf:type owl:AnnotationProperty .


#################################################################
#    Object Properties
#################################################################

###  http://purl.org/OpenPVSignal/OpenPVSignal.owl#Free_text_reporting_element
OpenPVSignal:Free_text_reporting_element rdf:type owl:ObjectProperty .


###  http://purl.org/mp/publishedBy
mp:publishedBy rdf:type owl:ObjectProperty .


###  http://purl.org/mp/references
mp:references rdf:type owl:ObjectProperty .


#################################################################
#    Data properties
#################################################################

###  http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_reporter_type
OpenPVSignal:has_reporter_type rdfs:subPropertyOf OpenPVSignal:has_registration_date .


#################################################################
#    Individuals
#################################################################

###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisDiscussionAndConclusion
:DiscussionAndConclusion rdf:type owl:NamedIndividual ,
                                  OpenPVSignal:Conclusion ,
                                  OpenPVSignal:Discussion ;
                         mp:references :Ref.12 ,
                                       :Ref.13 ,
                                       :Ref.14 ,
                                       :Ref.3 ,
                                       :Ref.4 ,
                                       :Ref.7 ,
                                       :Ref.8 ;
                         OpenPVSignal:has_content """The presented case series of eight ICSRs on the association of ustekinumab and vasculitis comprise a relatively small but noteworthy first signal on the occurrence of a potentially serious safety issue.
Ustekinumab has been associated with vasculitis as the only suspected drug in six cases from four reporting countries, all reported to have been used for a licensed indication. The potential for co- suspected drugs to affect the causality assessments were found only in two cases, consisting of TNF-α inhibitors and penicillin. The positive antinuclear factor test reported in case number 6 with ustekinumab as the single reported drug indicates the possibility of a similar mechanism of induction of vasculitis by this agent. Being the only IL-12/23 monoclonal antibody approved on the clinical market for the indications psoriasis and PsA, the assessment of a drug-class effect is however unattainable at this point.
In clinical trials, the presence of antibodies against ustekinumab as measured in psoriasis and PsA patients ranged from 3.8% to 6%.7,13 The majority of patients presenting antibodies to ustekinumab were found having neutralizing such of low titer.3,4 Another immunologically related reaction of interest is serum sickness, having no records of reported incidences during clinical trials with ustekinumab in psoriasis or in PsA patients.7,8,14 If yet rare, there are reported incidences of  serum sickness (PT serum sickness) associated with ustekinumab treatment reported to VigiBase, one of which is represented by case number 8) in the series reflected above. The referred ICSR does however indicate that a medication error related problem occurred (primary source stating suspected incorrect storage of drug), which may explain the unexpectedly long time-to-onset (866 days) and negative rechallenge when therapy was resumed. The reaction vasculitis has been reported with related clinical manifestations, such as arthralgia, haematuria, abdominal pain or confirmatory biopsy findings by laboratory data in cases 1 and 2. Increased anti-DNA antibody titer and hypocomplementemia were also recorded, if yet in an antinuclear antibody positive patient, having previous medical history of systemic lupus erythematosis. Observations of decreased creatinine clearance, increased C-reactive protein, serum-sickness and lupus erythematosus were reported in the case of suspected administration with incorrectly stored drug. In contrast to the idiopathic reaction, drug-induced vasculitis has been observed to have a milder course in terms of organ involvement and time-to-onset, 12 which is consistent with the reported findings mostly involving cutaneous reactions. Considering the compiled available information on the association of ustekinumab and vasculitis, there is support for a signal.""" ;
                         rdfs:label "Discussion and conclusion" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisHypersensitivityReactionsForUstekinumab
:HypersensitivityReactionsForUstekinumab rdf:type owl:NamedIndividual ,
                                                  OpenPVSignal:Statistical_Entity ;
                                         OpenPVSignal:refers_to_adverse_effect :anaphylaxis ,
                                                                               :angioedema ;
                                         OpenPVSignal:has_content "Serious hypersensitivity reactions, including anaphylaxis and angioedema, have been observed post-marketing and are labelled as rare (≥ 1/10,000 to < 1/1,000)." ;
                                         rdfs:label "Hypersensitivity reactions for ustekinumab" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisIC025ValueForUstekinumabAndVasculitis
:IC025ValueForUstekinumabAndVasculitis rdf:type owl:NamedIndividual ,
                                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Information_Component__025_(IC025)> ;
                                       OpenPVSignal:refers_to_adverse_effect :vasculitis ;
                                       OpenPVSignal:refers_to_drug :ustekinumab ;
                                       OpenPVSignal:refers_to_information_component :ICValueForUstekinumabAndVasculitis ;
                                       OpenPVSignal:has_value 0.12 ;
                                       OpenPVSignal:refers_to_number_of_reports 9 ;
                                       rdfs:label "IC025 value for ustekinumab and vasculitis" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisICValueForUstekinumabAndVasculitis
:ICValueForUstekinumabAndVasculitis rdf:type owl:NamedIndividual ,
                                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Information_Component_(IC)> ;
                                    OpenPVSignal:refers_to_adverse_effect :vasculitis ;
                                    OpenPVSignal:refers_to_drug :ustekinumab ;
                                    OpenPVSignal:has_value 1.21 ;
                                    OpenPVSignal:refers_to_number_of_reports 9 ;
                                    rdfs:label "IC value for ustekinumab and vasculitis" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisIntroductionContent
:IntroductionContent rdf:type owl:NamedIndividual ,
                              OpenPVSignal:Introduction ;
                     mp:references :Ref.1 ,
                                   :Ref.10 ,
                                   :Ref.11 ,
                                   :Ref.2 ,
                                   :Ref.3 ,
                                   :Ref.4 ,
                                   :Ref.5 ,
                                   :Ref.6 ,
                                   :Ref.7 ,
                                   :Ref.8 ,
                                   :Ref.9 ;
                     OpenPVSignal:has_content """Ustekinumab is described as a fully human IgG1κ monoclonal antibody to interleukin (IL)-12 and 23, binding to the shared p40 protein subunit of the corresponding human cytokines.1 IL-12 and IL-23 are heterodimeric cytokines produced by antigen presenting cells (e.g. macrophages and dendritic cells) and have been identified as key mediators in psoriasis pathophysiology.2 IL-12 triggers the proliferation of T helper type 1 (Th1) cells, with production of the important immunoregulator IFN-γ, while IL-23 is found over expressed in psoriasis plaques and stimulates the T helper type 17 (Th17) cells. By binding to the p40 subunit, ustekinumab inhibits the interaction of IL-12 and IL-23 with the IL-12Rβ1 receptor protein at the surface of immune cells, interrupting the following immune cascade.
Ustekinumab only has affinity to free IL-12 and IL- 23, why binding of p40 must take place prior to the competing receptor binding.2-4
The novel monoclonal antibody was first approved in 2008 by Health Canada, followed in 2009 by the EMA and the US FDA. It is today widely licensed for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for phototherapy or systemic therapy. In September 2013, the US FDA and EMA approved an additional indication for ustekinumab, which was extended to include active psoriatic arthritis (PsA) in adult patients, alone or in combination with ethotrexate.4 when the response to previous non-biological disease-modifying anti-rheumatic drug (DMARD)
therapy has been inadequate.3 There are currently no other approved IL-12/23 antibodies indicated in the treatment of adult psoriasis and PsA patients in the US or EU, although new candidates are under study.5
In population-based studies, the incidence of psoriasis in adults has been estimated to range between 78.9-230/100,000 person-years, the occurrence varying with geographic region and age.6 Considering the restricted indication for which ustekinumab has been licensed until recently, clinical experience of the antibody is somewhat limited. In clinical trials on psoriasis patients, no cases of serious hypersensitivity, e.g.  anaphylaxis or serum sickness-like reactions, were observed.7 Also based on the available phase III clinical trials data on short term safety (52 weeks) of ustekinumab in PsA patients, there are no reported incidences of serious hypersensitivity reactions.8,9 However, anaphylaxis and angioedema have been reported in association with ustekinumab therapy in post marketing settings.3,4
Vasculitis is a condition involving an inflammatory reaction damaging the wall of blood  vessels  that can lead to subsequent ischaemic damage of organs supplied by the blood vessels affected. It can be a primary manifestation of disease, e.g. as in Henoch Schönlein purpura, or a secondary manifestation of other conditions as seen with malignancies or with drug induced vasculitis. The underlying pathophysiological mechanism is considered at least partly immune mediated, as a response to an antigen in the context of an immune complex disease. Antineutrophil cytoplasmic antibodies (ANCA) have been associated with small vessel vasculitis as in Wegener granulomatosis or in drug induced vasculitis, e.g. by antithyroid drugs. The prevalence of drug induced vasculitis is unclear and drugs associated with it besides antithyroid drugs are antibiotics such as minocycline, TNF-α inhibitors such as adalimumab, etanercept and infliximab, and other medicines such as clozapine, allopurinol and others. Drug induced vasculitis often manifests in the skin and the subcutis but can affect also other organs.10,11
 """ ;
                     rdfs:label "Introduction content" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisLiteratureAndLabelling
:LiteratureAndLabelling rdf:type owl:NamedIndividual ,
                                 OpenPVSignal:Literature_information ;
                        mp:references :Ref.12 ,
                                      :Ref.14 ,
                                      :Ref.15 ,
                                      :Ref.16 ,
                                      :Ref.3 ,
                                      :Ref.4 ;
                        OpenPVSignal:has_content """To date, we have not found any case reports or other publications on ustekinumab and vasculitis in the literature.
Serious hypersensitivity reactions, including anaphylaxis and angioedema, have been observed post-marketing and are labelled as rare (≥ 1/10,000 to < 1/1,000). Rash and urticaria have been documented to occur in <1% of patients during the controlled periods of clinical studies and are labelled as uncommon in the EU.3
Data on immunogenicity from clinical trials estimated 6% of patients on ustekinumab to have developed antibodies to the agent. The detection of antibodies against ustekinumab was not apparently associated with hypersensitivity reactions.3,4 Agents from the therapeutically related class TNF-α inhibitors, e.g. the monoclonal antibodies adalimumab, etanercept and infliximab, have been labelled with immunologic reactions including cutaneous and/or systemic vasculitis.14-16 Repeated treatment with these agents has been observed to lead to the development of autoantibodies including antinuclear antibodies and ANCA, with the manifestation of clinical vasculitis in rare instances.12""" ;
                        rdfs:label "Literature and labelling" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisMechanismOfUstekinumab
:MechanismOfUstekinumab rdf:type owl:NamedIndividual ,
                                 OpenPVSignal:Mechanism ;
                        mp:references :Ref.1 ,
                                      :Ref.2 ,
                                      :Ref.3 ,
                                      :Ref.4 ;
                        OpenPVSignal:has_content """Ustekinumab is described as a fully human IgG1κ monoclonal antibody to interleukin (IL)-12 and 23, binding to the shared p40 protein subunit of the corresponding human cytokines.1 IL-12 and IL-23 are heterodimeric cytokines produced by antigen presenting cells (e.g. macrophages and dendritic cells) and have been identified as key mediators in psoriasis pathophysiology.2 IL-12 triggers the proliferation of T helper type 1 (Th1) cells, with production of the important immunoregulator IFN-γ, while IL-23 is found over expressed in psoriasis plaques and stimulates the T helper type 17 (Th17) cells. By binding to the p40 subunit, ustekinumab inhibits the interaction of IL-12 and IL-23 with the IL-12Rβ1 receptor protein at the surface of immune cells, interrupting the following immune cascade.
Ustekinumab only has affinity to free IL-12 and IL- 23, why binding of p40 must take place prior to the competing receptor binding.2-4""" ;
                        rdfs:label "Mechanism of ustekinumab" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisPatient1
:Patient1 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Patient ;
          OpenPVSignal:has_age 37 ;
          OpenPVSignal:has_gender "female" ;
          rdfs:label "Patient 1" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisPatient2
:Patient2 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Patient ;
          OpenPVSignal:has_age 44 ;
          OpenPVSignal:has_gender "female" ;
          rdfs:label "Patient 2" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisPatient3
:Patient3 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Patient ;
          OpenPVSignal:has_gender "male" ;
          rdfs:label "Patient 3" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisPatient4
:Patient4 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Patient ;
          OpenPVSignal:has_gender "female" ;
          rdfs:label "Patient 4" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisPatient5
:Patient5 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Patient ;
          OpenPVSignal:has_age 29 ;
          OpenPVSignal:has_gender "female" ;
          rdfs:label "Patient 5" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisPatient6
:Patient6 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Patient ;
          OpenPVSignal:has_gender "female" ;
          rdfs:label "Patient 6" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisPatient7
:Patient7 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Patient ;
          OpenPVSignal:has_age 64 ;
          OpenPVSignal:has_gender "female" ;
          rdfs:label "Patient 7" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisPatient8
:Patient8 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Patient ;
          OpenPVSignal:has_age 64 ;
          OpenPVSignal:has_gender "female" ;
          rdfs:label "Patient 8" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisPatient9
:Patient9 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Patient ;
          OpenPVSignal:has_age 58 ;
          OpenPVSignal:has_gender "female" ;
          rdfs:label "Patient 9" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisRef.1
:Ref.1 rdf:type owl:NamedIndividual ,
                OpenPVSignal:Bibliographic_reference ;
       OpenPVSignal:has_content "Krueger GG, Langley RG, Leonardi C, Yeilding N, Guzzo C, Wang Y et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med. 2007;356:580-92." ;
       rdfs:label "Ref.1" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisRef.10
:Ref.10 rdf:type owl:NamedIndividual ,
                 OpenPVSignal:Bibliographic_reference ;
        OpenPVSignal:has_content "Radić M. Drug-Induced Vasculitis, Advances in the Etiology, Pathogenesis and Pathology of Vasculitis. In: Amezcua-Guerra LM, ed.: InTech 2011." ;
        rdfs:label "Ref.10" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisRef.11
:Ref.11 rdf:type owl:NamedIndividual ,
                 OpenPVSignal:Bibliographic_reference ;
        OpenPVSignal:has_content "Langford CA, Fauci AS. The vasculitis syndromes. In: Fauci AS, Braunwald E, Kasper DL et al., eds. Harrison’s Principles of Internal Medicine. 17 ed 2011:2119-31." ;
        rdfs:label "Ref.11" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisRef.12
:Ref.12 rdf:type owl:NamedIndividual ,
                 OpenPVSignal:Bibliographic_reference ;
        OpenPVSignal:has_content "Radic M, Martinovic Kaliterna D, Radic J. Drug- induced vasculitis: a clinical and pathological review. Neth J Med. 2012;70:12-7." ;
        rdfs:label "Ref.12" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisRef.13
:Ref.13 rdf:type owl:NamedIndividual ,
                 OpenPVSignal:Bibliographic_reference ;
        OpenPVSignal:has_content "Gottlieb A, Narang K. Ustekinumab in the treatment of psoriatic arthritis: latest findings and clinical potential. Ther Adv Musculoskelet Dis. 2013;5:277-85." ;
        rdfs:label "Ref.13" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisRef.14
:Ref.14 rdf:type owl:NamedIndividual ,
                 OpenPVSignal:Bibliographic_reference ;
        OpenPVSignal:has_content "Summary of Product Characteristics for adalimumab (Humira) URL:http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000481/WC500050870.pdf. Accessed: 5 November 2013." ;
        rdfs:label "Ref.14" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisRef.15
:Ref.15 rdf:type owl:NamedIndividual ,
                 OpenPVSignal:Bibliographic_reference ;
        OpenPVSignal:has_content "Summary of Product Characteristics for etanercept (Enbrel). URL: http://www.ema.europa.eu/docs/en_ GB/document_library/EPAR_-_Product_Information/ human/000262/WC500027361.pdf. Accessed: 5 November 2013" ;
        rdfs:label "Ref.15" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisRef.16
:Ref.16 rdf:type owl:NamedIndividual ,
                 OpenPVSignal:Bibliographic_reference ;
        OpenPVSignal:has_content "Summary of Product Characteristics for infliximab (Remicade). URL: http://www.ema.europa.eu/docs/en_ GB/document_library/EPAR_-_Product_Information/ human/000240/WC500050888.pdf. Accessed: 5 November 2013." ;
        rdfs:label "Ref.16" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisRef.2
:Ref.2 rdf:type owl:NamedIndividual ,
                OpenPVSignal:Bibliographic_reference ;
       OpenPVSignal:has_content "Mitra A, Fallen RS, Lima HC. Cytokine-based therapy in psoriasis. Clin Rev Allergy Immunol 2013; 44: 173- 82." ;
       rdfs:label "Ref.2" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisRef.3
:Ref.3 rdf:type owl:NamedIndividual ,
                OpenPVSignal:Bibliographic_reference ;
       OpenPVSignal:has_content "Summary of Product Characteristics for STELARA 45 mg solution for injection. URL:http://www. ema.europa.eu /docs/en_GB/document_library/EPAR_-_Product_Information /human/000958/WC500058513. pdf Accessed: 14 October 2013." ;
       rdfs:label "Ref.3" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisRef.4
:Ref.4 rdf:type owl:NamedIndividual ,
                OpenPVSignal:Bibliographic_reference ;
       OpenPVSignal:has_content "US FDA label for STELARA (ustekinumab). URL: http://www.accessdata.fda.gov/drugsatfda_docs/ label/2013/125261s103lbl.pdf. Accessed: 14 Oct 2013." ;
       rdfs:label "Ref.4" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisRef.5
:Ref.5 rdf:type owl:NamedIndividual ,
                OpenPVSignal:Bibliographic_reference ;
       OpenPVSignal:has_content "Langley RG, Papp K, Gottlieb AB, Krueger GG, Gordon KB, Williams D et al. Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis. J Eur Acad Dermatol Venereol. 2013;27:1252-61." ;
       rdfs:label "Ref.5" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisRef.6
:Ref.6 rdf:type owl:NamedIndividual ,
                OpenPVSignal:Bibliographic_reference ;
       OpenPVSignal:has_content "Parisi R, Symmons DP, Griffiths CE, Ashcroft DM.Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133:377-85." ;
       rdfs:label "Ref.6" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisRef.7
:Ref.7 rdf:type owl:NamedIndividual ,
                OpenPVSignal:Bibliographic_reference ;
       OpenPVSignal:has_content "Papp KA, Griffiths CE, Gordon K, Lebwohl M, Szapary PO, Wasfi Y et al. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. Br J Dermatol. 2013;168:844-54." ;
       rdfs:label "Ref.7" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisRef.8
:Ref.8 rdf:type owl:NamedIndividual ,
                OpenPVSignal:Bibliographic_reference ;
       OpenPVSignal:has_content "McInnes IB, Kavanaugh A, Gottlieb AB, Puig L, Rahman P, Ritchlin C et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double- blind, placebo-controlled PSUMMIT 1 trial. Lancet 2013;382:780-9." ;
       rdfs:label "Ref.8" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisRef.9
:Ref.9 rdf:type owl:NamedIndividual ,
                OpenPVSignal:Bibliographic_reference ;
       OpenPVSignal:has_content "Ritchlin C, Gottlieb A, McInnes I, Puig L, Rahman P, Li S et al. Ustekinumab in active psoriatic arthritis including patients previously treated with anti-TNF agents: results of a phase 3, multiCentre, double-blind, placebo- controlled study. Arthritis Rheum. 2012:64:S1080–S1." ;
       rdfs:label "Ref.9" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisReport1
:Report1 rdf:type owl:NamedIndividual ,
                  OpenPVSignal:VigiBase_Report ;
         OpenPVSignal:refers_to_adverse_effect :vasculitis ;
         OpenPVSignal:refers_to_patient :Patient1 ;
         OpenPVSignal:refers_to_primary_suspect_drug :ustekinumab ;
         OpenPVSignal:refers_to_country "http://dbpedia.org/resource/Greece" ;
         rdfs:label "Report 1" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisReport2
:Report2 rdf:type owl:NamedIndividual ,
                  OpenPVSignal:VigiBase_Report ;
         OpenPVSignal:refers_to_adverse_effect :abdominalPain ,
                                               :arthralgia ,
                                               :haematuria ,
                                               :vasculitis ;
         OpenPVSignal:refers_to_concomitant_drug :ramipril ;
         OpenPVSignal:refers_to_patient :Patient2 ;
         OpenPVSignal:refers_to_primary_suspect_drug :ustekinumab ;
         OpenPVSignal:refers_to_country "http://dbpedia.org/resource/United_Kingdom" ;
         rdfs:label "Report 2" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisReport3
:Report3 rdf:type owl:NamedIndividual ,
                  OpenPVSignal:VigiBase_Report ;
         OpenPVSignal:refers_to_adverse_effect :medicineIneffective ,
                                               :vasculitis ;
         OpenPVSignal:refers_to_concomitant_drug :indometacin ,
                                                 :omeprazole ;
         OpenPVSignal:refers_to_patient :Patient3 ;
         OpenPVSignal:refers_to_primary_suspect_drug :ustekinumab ;
         OpenPVSignal:time_to_onset :onset3 ;
         OpenPVSignal:refers_to_country "http://dbpedia.org/resource/United_States" ;
         rdfs:label "Report 3" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisReport4
:Report4 rdf:type owl:NamedIndividual ,
                  OpenPVSignal:VigiBase_Report ;
         OpenPVSignal:refers_to_adverse_effect :vasculitis ;
         OpenPVSignal:refers_to_concomitant_drug :amoxicillin ,
                                                 :cilazapril ,
                                                 :metformin ;
         OpenPVSignal:refers_to_patient :Patient4 ;
         OpenPVSignal:refers_to_primary_suspect_drug :ustekinumab ;
         OpenPVSignal:refers_to_country "http://dbpedia.org/resource/Canada" ;
         rdfs:label "Report 4" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisReport5
:Report5 rdf:type owl:NamedIndividual ,
                  OpenPVSignal:VigiBase_Report ;
         OpenPVSignal:refers_to_adverse_effect :vasculitis ;
         OpenPVSignal:refers_to_concomitant_drug :acitretin ,
                                                 :adalimumab ,
                                                 :ciclosporin ,
                                                 :etanercept ,
                                                 :methotrexate ;
         OpenPVSignal:refers_to_patient :Patient5 ;
         OpenPVSignal:refers_to_primary_suspect_drug :ustekinumab ;
         OpenPVSignal:refers_to_secondary_suspect_drug :infliximab ;
         OpenPVSignal:time_to_onset :onset5 ;
         OpenPVSignal:refers_to_country "http://dbpedia.org/resource/Spain" ;
         rdfs:label "Report 5" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisReport6
:Report6 rdf:type owl:NamedIndividual ,
                  OpenPVSignal:VigiBase_Report ;
         OpenPVSignal:has_free_text_reporting_element :case6 ;
         OpenPVSignal:refers_to_adverse_effect :antinuclearFactorTestPositive ,
                                               :complementFactorAbnormality ,
                                               :vasculitis ;
         OpenPVSignal:refers_to_patient :Patient6 ;
         OpenPVSignal:refers_to_primary_suspect_drug :ustekinumab ;
         OpenPVSignal:refers_to_country "http://dbpedia.org/resource/Canada" ;
         rdfs:label "Report 6" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisReport7
:Report7 rdf:type owl:NamedIndividual ,
                  OpenPVSignal:VigiBase_Report ;
         OpenPVSignal:refers_to_adverse_effect :diarrhoea ,
                                               :hypotension ,
                                               :malaise ,
                                               :pruritus ,
                                               :rash ,
                                               :respiratoryDepression ,
                                               :somnolence ,
                                               :tachycardia ,
                                               :vasculitis ;
         OpenPVSignal:refers_to_patient :Patient7 ;
         OpenPVSignal:refers_to_primary_suspect_drug :ustekinumab ;
         OpenPVSignal:time_to_onset :onset7 ;
         OpenPVSignal:refers_to_country "http://dbpedia.org/resource/United_Kingdom" ;
         rdfs:label "Report 7" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisReport8
:Report8 rdf:type owl:NamedIndividual ,
                  OpenPVSignal:VigiBase_Report ;
         OpenPVSignal:has_free_text_reporting_element :case8 ;
         OpenPVSignal:refers_to_adverse_effect :abdominalPain ,
                                               :c-reactiveProteinIncreased ,
                                               :creatinineClearanceDecreased ,
                                               :dyspnoea ,
                                               :injectionSiteRash ,
                                               :leRash ,
                                               :medicationErrorRelatedProblems ,
                                               :rash ,
                                               :serumSickness ,
                                               :somnolence ,
                                               :vasculitis ;
         OpenPVSignal:refers_to_concomitant_drug :levothyroxine ;
         OpenPVSignal:refers_to_patient :Patient8 ;
         OpenPVSignal:refers_to_primary_suspect_drug :ustekinumab ;
         OpenPVSignal:time_to_onset :onset8 ;
         OpenPVSignal:refers_to_country "http://dbpedia.org/resource/United_Kingdom" ;
         rdfs:label "Report 8" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisReport9
:Report9 rdf:type owl:NamedIndividual ,
                  OpenPVSignal:VigiBase_Report ;
         OpenPVSignal:refers_to_adverse_effect :vasculitis ;
         OpenPVSignal:refers_to_concomitant_drug :alprazolam ,
                                                 :fexofenadine ,
                                                 :glipizide ,
                                                 :lisinopril ,
                                                 :metformin ,
                                                 :salbutamol ,
                                                 :venlafaxine ,
                                                 <http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitis#fluticasonepropionate/salmeterolXinafoate> ;
         OpenPVSignal:refers_to_patient :Patient9 ;
         OpenPVSignal:refers_to_primary_suspect_drug :ustekinumab ;
         OpenPVSignal:refers_to_secondary_suspect_drug :amoxicillin ,
                                                       :etanercept ;
         OpenPVSignal:time_to_onset :onset9 ;
         OpenPVSignal:refers_to_country "http://dbpedia.org/resource/United_States" ;
         rdfs:label "Report 9" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisReportsInVigibase
:ReportsInVigibase rdf:type owl:NamedIndividual ,
                            OpenPVSignal:Free_text_reporting_element ;
                   mp:references :Ref.3 ,
                                 :Ref.4 ;
                   OpenPVSignal:has_content """Nine cases of vasculitis with ustekinumab were reported to the WHO Global Individual Case Safety
Report (ICSR) Database, VigiBaseTM between late 2010 to mid 2013; the association was detected as disproportionally reported with an IC value of 1.21 (IC025 0.12). Upon review, two of the cases were identified as duplicates, therefore only the most informative version was included in the case series of eight unique ICSRs. The cases originate from United Kingdom, United States, Canada, Spain and Greece: seven spontaneous reports and one report from a study. Among the spontaneous reports, six were reported by a physician or other health professional, while one was from the literature. The demographics of this case series are presented in Table 1 and further described below.
The age span of the patients ranges between 29 to 64 years and the gender distribution is dominated by females (7/8 subjects). Ustekinumab is the single suspected drug in six cases, concomitant medication being reported in four of these. The remaining two cases contained at least one other co-suspected drug, respectively.
Psoriasis was specified as the indication for treatment in all eight ICSRs. The reaction was further specified as cutaneous vasculitis in two reports and leukocytoclastic vasculitis in two, with no additional description in the remaining four. Time-to-onset information including dates for start of ustekinumab treatment and onset of vasculitis was provided in four cases. However, narrative information presented estimates for the timeliness of the reaction in one additional case, with recurring vasculitis “one week 
after 3rd and 4th dose” of ustekinumab therapy. Considering the dose regimen of ustekinumab therapy starting as subcutaneous injections at weeks 4, 16 and 28,3,4 the time to onset may be estimated to 119-203 days for the reflected case. Dechallenge of ustekinumab was reported in three cases, one of which having records of reaction abating and a second having outcome recovering at the time of reporting. Two cases of negative rechallenge were also reported, one of which in association with a medication error related problem (incorrect storage of drug). The overall outcomes were recovered (or recovering) in four, not recovered in one, unknown in one and not reported in two cases. No fatalities were reported.""" ;
                   rdfs:label "Reports in vigibase" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisResponse_from_Janssen
:Response_from_Janssen rdf:type owl:NamedIndividual ,
                                OpenPVSignal:Response_to_Pharmacovigilance_Signal_Report ;
                       OpenPVSignal:refers_to_pharmacovigilance_signal_report :Ustekinumab_and_vasculitis ;
                       OpenPVSignal:has_content "Methods The Marketing Authorization Holder (MAH) of ustekinumab (Stelara®) performed a comprehensive search of the Global Medical Safety Database using the MedDRA SMQ for Vasculitis (narrow) to identify all solicited and unsolicited cases of vasculitis including cases from clinical trials, spontaneous reports, and postmarketing studies reported through 15 October 2013. Results The search identified 20 cases, which included 7 of the 8 unique cases referenced in the WHO report. The eighth case (ICSR No 5) was not included in the MAH Safety Database and was added resulting in a total of 21 cases. Of these 21 cases, 1 case was excluded due to duplication and another case was excluded as the event occurred before the treatment with ustekinumab. Thus 19 cases were included in the analysis. Case characteristics of these 19 cases are provided in Table 1: A review of these 19 cases (see Table 2) showed that in 2 cases, vasculitis was assessed by the reporter as unrelated to treatment with ustekinumab; in 3 cases, the information reported was very limited and inadequate for medical assessment; and in 11 cases, the patients had one or more confounding factors, plausible alternative explanations that could have contributed to the event of vasculitis, or clinical features not typical for a diagnosis of vasculitis. The remaining 3 cases of interest are discussed below. Case 1 Was reported by a 48-year-old female (weight 345 lbs), ex-smoker who initiated ustekinumab (dose, date unspecified) for psoriasis. Approximately 2 months after starting ustekinumab, she stated that she was diagnosed with “Widners vasculitis” (possibly implying Wegener’s granulomatosis) with symptoms of blurred vision, selective memory, painful joints, and difficulty with walking. Treatment with ustekinumab was discontinued 4 months after initiation for complaints of “feeling bad” and “coughs with blood.” She was treated in the intensive care unit and was discharged after 2 weeks. Treatment included kidney dialysis every other day for 2 months. Outcome of the treatment could not be received. MAH Comment: While the reported events of blurred vision, selective memory, painful joints, feeling bad, and haemoptysis with reported vasculitis may resemble Wegener’s granulomatosis, the diagnosis was not confirmed medically with biopsy and cytoplasmic anti-neutrophil cytoplasmic antibody (cANCA) results. In the absence of information on medical history, concomitant medications, comorbidities, and corrective treatments, a definite causal relationship to the treatment with ustekinumab cannot be established. Wegener’s granulomatosis is an autoimmune disorder and generally not viewed as a drug- induced disease. Further, it is unclear if the obesity (345 lbs) in this patient was associated with other comorbidities such as diabetes, hypertension, atherosclerosis, renal disorders, and if the medical evaluation included glomerulonephritis, sarcoidosis, lymphomatoid granulomatosis, NK/T-cell lymphoma, systemic lupus erythematosus etc. as part of the differential diagnosis. Case 2 A 58-year-old female (weight 169 lbs) with a history of hysterectomy, hypersensitivity to calcipotriol, penicillin, and sulfacetamide was treated with ustekinumab 45 mg for psoriasis. Concomitant medications included methotrexate, clobetasol, conjugated estrogens, tolterodine, and folic acid. After the first injection, she experienced a vasculitic-like rash (with numerous guttate papules) on the left chest, left arm, and left lower extremity, which turned into a severe vasculitic eruption after the second injection. The treating physician stated that a biopsy was not performed and the appearance on photos was vasculitis. Ustekinumab was discontinued. Corrective treatment included ciprofloxacin and the eruptions resolved 2 months later. MAH Comment: While vasculitis could be diagnosed by its clinical signs and symptoms, a definitive diagnosis of vasculitis could not be affirmed based on the available information without the results of biopsy and/or ANCA antibodies. The unilateral presentation of vasculitic-like rash reported in this patient is uncharacteristic of drug-induced vasculitis. Case 3 WHO ICSR No 1) described a 37-year-old female treated with ustekinumab 45 mg for psoriasis. She experienced 2 episodes of pruritic bullous rash on lower extremities 1 week after the third and 1 week after the fourth dose, which was diagnosed as “medicinal vasculitis” based on biopsy. The patient recovered “1 week later.” No other information was reported. MAH Comment: There is insufficient information on medical history and concomitant medications available to make an adequate assessment of a drug-event relationship. Conclusion The safety profile of ustekinumab has been well established since its approval 5 years ago. An evaluation of the reported cases does not support vasculitis as an adverse drug reaction related to the treatment with ustekinumab. The biologic plausibility and role of anti-IL-12/23 monoclonal antibodies in the pathogenesis of different types of vasculitis is not fully understood. The MAH continues to monitor vasculitis through routine pharmacovigilance activities." ;
                       rdfs:label "Response from Janssen" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisSignalOriginality
:SignalOriginality rdf:type owl:NamedIndividual ,
                            obo:OAE_0001197 ;
                   OpenPVSignal:has_content "To date, we have not found any case reports or other publications on ustekinumab and vasculitis in the literature." ;
                   rdfs:label "Signal originality" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisSummaryContent
:SummaryContent rdf:type owl:NamedIndividual ,
                         OpenPVSignal:Summary ;
                OpenPVSignal:has_content """Ustekinumab is a relatively new monoclonal antibody that prevents the binding of IL-12 and IL-23 to their respective receptors. Since its introduction on the clinical market, in late 2008, it has been licensed for the treatment of plaque psoriasis, but was recently further approved for the indication psoriatic arthritis.
Clinical experience with ustekinumab appears limited, perhaps reflecting the restricted indication for use until recently. No incidences of serious hypersensitivity reactions were recorded during clinical trials for either of the approved indications.
However, cases of anaphylaxis and angioedema have occurred post marketing. A case series of eight reports on the association of ustekinumab and vasculitis, reported from five different countries to the WHO Global Individual Case Safety Report Database, VigiBaseTM has been assessed.The association has been statistically disproportionately reported and current information supports a signal on the risk of vasculitis with ustekinumab.""" ;
                rdfs:label "Summary content" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisTNFa_inhibitors_and_vasculitis
:TNFa_inhibitors_and_vasculitis rdf:type owl:NamedIndividual ,
                                         obo:OAE_0001182 ,
                                         OpenPVSignal:Warning_Information ;
                                OpenPVSignal:refers_to_adverse_effect :cutaneousVasculitis ,
                                                                      :vasculitis ;
                                OpenPVSignal:refers_to_drug :adalimumab ,
                                                            :etanercept ,
                                                            :infliximab ;
                                mp:references :Ref.12 ,
                                              :Ref.14 ,
                                              :Ref.15 ,
                                              :Ref.16 ;
                                OpenPVSignal:has_content "Agents from the therapeutically related class TNF-α inhibitors, e.g. the monoclonal antibodies adalimumab, etanercept and infliximab, have been labelled with immunologic reactions including cutaneous and/or systemic vasculitis.14-16 Repeated treatment with these agents has been observed to lead to the development of autoantibodies including antinuclear antibodies and ANCA, with the manifestation of clinical vasculitis in rare instances.12" ;
                                rdfs:label "TNFa inhibitors and vasculitis" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisUppsala_Monitoring_Centre
:Uppsala_Monitoring_Centre rdf:type owl:NamedIndividual ,
                                    prov:Organization ;
                           rdfs:label "Uppsala Monitoring Centre" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisUstekinumab_and_vasculitis
:Ustekinumab_and_vasculitis rdf:type owl:NamedIndividual ,
                                     OpenPVSignal:Pharmacovigilance_Signal_Report ;
                            OpenPVSignal:refers_to_author :Uppsala_Monitoring_Centre ;
                            OpenPVSignal:refers_to_signal :pvSignal ;
                            mp:publishedBy :Uppsala_Monitoring_Centre ;
                            OpenPVSignal:has_creation_date "01/07/2014" ;
                            OpenPVSignal:has_overall_conclusion "causal association" ;
                            rdfs:label "Ustekinumab and vasculitis" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisVasculitis
:Vasculitis rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Free_text_reporting_element ;
            OpenPVSignal:refers_to_adverse_effect :vasculitis ;
            OpenPVSignal:refers_to_drug :adalimumab ,
                                        :allopurinol ,
                                        :antithyroidDrugs ,
                                        :clozapine ,
                                        :etanercept ,
                                        :infliximab ,
                                        :minocycline ;
            mp:references :Ref.10 ,
                          :Ref.11 ;
            OpenPVSignal:has_content "Vasculitis is a condition involving an inflammatory reaction damaging the wall of blood vessels that can lead to subsequent ischaemic damage of organs supplied by the blood vessels affected. It can be a primary manifestation of disease, e.g. as in Henoch Schönlein purpura, or a secondary manifestation of other conditions as seen with malignancies or with drug induced vasculitis. The underlying pathophysiological mechanism is considered at least partly immune mediated, as a response to an antigen in the context of an immune complex disease. Antineutrophil cytoplasmic antibodies (ANCA) have been associated with small vessel vasculitis as in Wegener granulomatosis or in drug induced vasculitis, e.g. by antithyroid drugs. The prevalence of drug induced vasculitis is unclear and drugs associated with it besides antithyroid drugs are antibiotics such as minocycline, TNF-α inhibitors such as adalimumab, etanercept and infliximab, and other medicines such as clozapine, allopurinol and others. Drug induced vasculitis often manifests in the skin and the subcutis but can affect also other organs. 10,11" ;
            rdfs:label "Vasculitis pathophysiology" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisabdominalPain
:abdominalPain rdf:type owl:NamedIndividual ,
                        OpenPVSignal:Adverse_Effect ;
               OpenPVSignal:has_MedDRA_code 10000081 ;
               OpenPVSignal:has_MedDRA_prefered_term "Abdominal pain" ;
               rdfs:label "abdominal pain" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisacitretin
:acitretin rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Drug ;
           OpenPVSignal:has_ATC_code "D05BB02" ;
           rdfs:label "acitretin" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisadalimumab
:adalimumab rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Drug ;
            OpenPVSignal:has_ATC_code "L04AB04" ;
            rdfs:label "adalimumab" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisallopurinol
:allopurinol rdf:type owl:NamedIndividual ,
                      OpenPVSignal:Drug ;
             OpenPVSignal:has_ATC_code "M04AA01" ;
             rdfs:label "allopurinol" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisalprazolam
:alprazolam rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Drug ;
            OpenPVSignal:has_ATC_code "N05BA12" ;
            rdfs:label "alprazolam" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisamoxicillin
:amoxicillin rdf:type owl:NamedIndividual ,
                      OpenPVSignal:Drug ;
             OpenPVSignal:has_ATC_code "A02BD01" ,
                                       "A02BD03" ,
                                       "A02BD04" ,
                                       "A02BD05" ,
                                       "A02BD06" ,
                                       "A02BD07" ,
                                       "A02BD10" ,
                                       "A02BD11" ,
                                       "J01CA04" ,
                                       "J01CR02" ,
                                       "J01CR50" ;
             rdfs:label "amoxicillin" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisanaphylaxis
:anaphylaxis rdf:type owl:NamedIndividual ,
                      OpenPVSignal:Adverse_Effect ;
             OpenPVSignal:has_MedDRA_code 10002198 ;
             OpenPVSignal:has_MedDRA_prefered_term "Anaphylactic reaction" ;
             rdfs:label "anaphylaxis" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisangioedema
:angioedema rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Adverse_Effect ;
            OpenPVSignal:has_MedDRA_code 10002424 ;
            OpenPVSignal:has_MedDRA_prefered_term "Angioedema" ;
            rdfs:label "angioedema" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisantibodiesAgainstUstekinumab
:antibodiesAgainstUstekinumab rdf:type owl:NamedIndividual ,
                                       OpenPVSignal:Clinical_trial_information ;
                              OpenPVSignal:is_supported_by_statistical_entity :dataOnImmunogenicityOfUstekinumab ;
                              OpenPVSignal:refers_to_adverse_effect :psoriasis ,
                                                                    :psoriaticArthritis ;
                              OpenPVSignal:refers_to_drug :ustekinumab ;
                              mp:references :Ref.13 ,
                                            :Ref.3 ,
                                            :Ref.4 ,
                                            :Ref.7 ;
                              OpenPVSignal:has_content "Data on immunogenicity from clinical trials estimated 6% of patients on ustekinumab to have developed antibodies to the agent. The detection of antibodies against ustekinumab was not apparently associated with hypersensitivity reactions.3,4" ,
                                                       "In clinical trials, the presence of antibodies against ustekinumab as measured in psoriasis and PsA patients ranged from 3.8% to 6%.7,13 The majority of patients presenting antibodies to ustekinumab were found having neutralizing such of low titer.3,4" ;
                              rdfs:label "antibodies against ustekinumab" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisantinuclearFactorTestPositive
:antinuclearFactorTestPositive rdf:type owl:NamedIndividual ,
                                        OpenPVSignal:Adverse_Effect ;
                               OpenPVSignal:has_MedDRA_code 10060055 ;
                               OpenPVSignal:has_MedDRA_prefered_term "Antinuclear antibody positive" ;
                               rdfs:label "antinuclear factor test positive" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisantithyroidDrugs
:antithyroidDrugs rdf:type owl:NamedIndividual ,
                           OpenPVSignal:Drug ;
                  OpenPVSignal:has_ATC_code "H03B" ;
                  rdfs:label "antithyroid drugs" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisarthralgia
:arthralgia rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Adverse_Effect ;
            OpenPVSignal:has_MedDRA_code 10003239 ;
            OpenPVSignal:has_MedDRA_prefered_term "Arthralgia" ;
            rdfs:label "arthralgia" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisc-reactiveProteinIncreased
:c-reactiveProteinIncreased rdf:type owl:NamedIndividual ,
                                     OpenPVSignal:Adverse_Effect ;
                            OpenPVSignal:has_MedDRA_code 10006825 ;
                            OpenPVSignal:has_MedDRA_prefered_term "C-reactive protein increased" ;
                            rdfs:label "c-reactive protein increased" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitiscase6
:case6 rdf:type owl:NamedIndividual ,
                OpenPVSignal:Case_Report_Information ;
       OpenPVSignal:has_content "The positive antinuclear factor test reported in case number 6 with ustekinumab as the single reported drug indicates the possibility of a similar mechanism of induction of vasculitis by this agent." ;
       rdfs:label "info case 6" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitiscase8
:case8 rdf:type owl:NamedIndividual ,
                OpenPVSignal:Case_Report_Information ;
       OpenPVSignal:has_content "If yet rare, there are reported incidences of serum sickness (PT serum sickness) associated with ustekinumab treatment reported to VigiBase, one of which is represented by case number 8) in the series reflected above. The referred ICSR does however indicate that a medication error related problem occurred (primary source stating suspected incorrect storage of drug), which may explain the unexpectedly long time-to-onset (866 days) and negative rechallenge when therapy was resumed" ;
       rdfs:label "info case 8" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisciclosporin
:ciclosporin rdf:type owl:NamedIndividual ,
                      OpenPVSignal:Drug ;
             OpenPVSignal:has_ATC_code "L04AD01" ,
                                       "S01XA18" ;
             rdfs:label "ciclosporin" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitiscilazapril
:cilazapril rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Drug ;
            OpenPVSignal:has_ATC_code "C09AA08" ,
                                      "C09BA08" ;
            rdfs:label "cilazapril" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisclozapine
:clozapine rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Drug ;
           OpenPVSignal:has_ATC_code "N05ah02" ;
           rdfs:label "clozapine" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitiscomplementFactorAbnormality
:complementFactorAbnormality rdf:type owl:NamedIndividual ,
                                      OpenPVSignal:Adverse_Effect ;
                             OpenPVSignal:has_MedDRA_code 10061047 ;
                             OpenPVSignal:has_MedDRA_prefered_term "Complement factor abnormal" ;
                             rdfs:label "complement factor abnormality" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitiscreatinineClearanceDecreased
:creatinineClearanceDecreased rdf:type owl:NamedIndividual ,
                                       OpenPVSignal:Adverse_Effect ;
                              OpenPVSignal:has_MedDRA_code 10011372 ;
                              OpenPVSignal:has_MedDRA_prefered_term "Creatinine renal clearance decreased" ;
                              rdfs:label "creatinine clearance decreased" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitiscutaneousVasculitis
:cutaneousVasculitis rdf:type owl:NamedIndividual ,
                              OpenPVSignal:Adverse_Effect ;
                     OpenPVSignal:has_MedDRA_code 10011686 ;
                     OpenPVSignal:has_MedDRA_prefered_term "Cutaneous vasculitis" ;
                     rdfs:label "cutaneous vasculitis" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisdataOnImmunogenicityOfUstekinumab
:dataOnImmunogenicityOfUstekinumab rdf:type owl:NamedIndividual ,
                                            OpenPVSignal:Statistical_Entity ;
                                   OpenPVSignal:has_value 0.06 ;
                                   rdfs:label "data on immunogenicity of ustekinumab" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisdiarrhoea
:diarrhoea rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Adverse_Effect ;
           OpenPVSignal:has_MedDRA_code 10012735 ;
           OpenPVSignal:has_MedDRA_prefered_term "Diarrhoea" ;
           rdfs:label "diarrhoea" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisdyspnoea
:dyspnoea rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Adverse_Effect ;
          OpenPVSignal:has_MedDRA_code 10013968 ;
          OpenPVSignal:has_MedDRA_prefered_term "Dyspnoea" ;
          rdfs:label "dyspnoea" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisetanercept
:etanercept rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Drug ;
            OpenPVSignal:has_ATC_code "L04AB01" ;
            rdfs:label "etanercept" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisfexofenadine
:fexofenadine rdf:type owl:NamedIndividual ,
                       OpenPVSignal:Drug ;
              OpenPVSignal:has_ATC_code "R06AX26" ;
              rdfs:label "fexofenadine" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisglipizide
:glipizide rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Drug ;
           OpenPVSignal:has_ATC_code "A10BB07" ;
           rdfs:label "glipizide" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitishaematuria
:haematuria rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Adverse_Effect ;
            OpenPVSignal:has_MedDRA_code 10018867 ;
            OpenPVSignal:has_MedDRA_prefered_term "Haematuria" ;
            rdfs:label "haematuria" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitishypotension
:hypotension rdf:type owl:NamedIndividual ,
                      OpenPVSignal:Adverse_Effect ;
             OpenPVSignal:has_MedDRA_code 10021097 ;
             OpenPVSignal:has_MedDRA_prefered_term "Hypotension" ;
             rdfs:label "hypotension" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisincidenceOfPsoriasis
:incidenceOfPsoriasis rdf:type owl:NamedIndividual ,
                               OpenPVSignal:Incidence ,
                               [ rdf:type owl:Restriction ;
                                 owl:onProperty OpenPVSignal:has_value ;
                                 owl:someValuesFrom [ rdf:type rdfs:Datatype ;
                                                      owl:onDatatype xsd:decimal ;
                                                      owl:withRestrictions ( [ xsd:minInclusive 0.000789
                                                                             ]
                                                                             [ xsd:maxInclusive 0.0023
                                                                             ]
                                                                           )
                                                    ]
                               ] ;
                      OpenPVSignal:refers_to_adverse_effect :psoriasis ;
                      mp:references :Ref.6 ;
                      OpenPVSignal:has_content "In population-based studies, the incidence of psoriasis in adults has been estimated to range between 78.9-230/100,000 person-years, the occurrence varying with geographic region and age.6 " ;
                      rdfs:label "incidence of psoriasis" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisindometacin
:indometacin rdf:type owl:NamedIndividual ,
                      OpenPVSignal:Drug ;
             OpenPVSignal:has_ATC_code "C01EB03" ,
                                       "M01AB01" ,
                                       "M02AA23" ,
                                       "S01BC01" ;
             rdfs:label "indometacin" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisinfliximab
:infliximab rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Drug ;
            OpenPVSignal:has_ATC_code "L04AB02" ;
            rdfs:label "infliximab" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisinjectionSiteRash
:injectionSiteRash rdf:type owl:NamedIndividual ,
                            OpenPVSignal:Adverse_Effect ;
                   OpenPVSignal:has_MedDRA_code 10022094 ;
                   OpenPVSignal:has_MedDRA_prefered_term "Injection site rash" ;
                   rdfs:label "injection site rash" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisleRash
:leRash rdf:type owl:NamedIndividual ,
                 OpenPVSignal:Adverse_Effect ;
        OpenPVSignal:has_MedDRA_code 10042946 ;
        OpenPVSignal:has_MedDRA_prefered_term "Systemic lupus erythematosus rash" ;
        rdfs:label "lupus erythematous rash" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisleukocytoclastic_vasculitis
:leukocytoclastic_vasculitis rdf:type owl:NamedIndividual ,
                                      OpenPVSignal:Adverse_Effect ;
                             OpenPVSignal:has_MedDRA_code 10024377 ;
                             OpenPVSignal:has_MedDRA_prefered_term "Leukocytoclastic vasculitis" ;
                             rdfs:label "leukocytoclastic vasculitis" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitislevothyroxine
:levothyroxine rdf:type owl:NamedIndividual ,
                        OpenPVSignal:Drug ;
               OpenPVSignal:has_ATC_code "H03AA01" ;
               rdfs:label "levothyroxine" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitislisinopril
:lisinopril rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Drug ;
            OpenPVSignal:has_ATC_code "C09AA03" ,
                                      "C09BA03" ,
                                      "C09BB03" ,
                                      "C10BX07" ;
            rdfs:label "lisinopril" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitismalaise
:malaise rdf:type owl:NamedIndividual ,
                  OpenPVSignal:Adverse_Effect ;
         OpenPVSignal:has_MedDRA_code 10025482 ;
         OpenPVSignal:has_MedDRA_prefered_term "Malaise" ;
         rdfs:label "malaise" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitismedicationErrorRelatedProblems
:medicationErrorRelatedProblems rdf:type owl:NamedIndividual ,
                                         OpenPVSignal:Adverse_Effect ;
                                OpenPVSignal:has_ICD_code "T88.7" ;
                                OpenPVSignal:has_MedDRA_code 10027091 ;
                                OpenPVSignal:has_MedDRA_prefered_term "Medication error" ;
                                rdfs:label "medication error related problems" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitismedicineIneffective
:medicineIneffective rdf:type owl:NamedIndividual ,
                              OpenPVSignal:Adverse_Effect ;
                     OpenPVSignal:has_ICD_code "Z16.30" ;
                     OpenPVSignal:has_MedDRA_code 10013709 ;
                     OpenPVSignal:has_MedDRA_prefered_term "Drug ineffective" ;
                     rdfs:label "medicine ineffective" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitismetformin
:metformin rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Drug ;
           OpenPVSignal:has_ATC_code "A10BA02" ,
                                     "A10BD02" ,
                                     "A10BD03" ,
                                     "A10BD05" ,
                                     "A10BD07" ,
                                     "A10BD08" ,
                                     "A10BD10" ,
                                     "A10BD11" ,
                                     "A10BD13" ,
                                     "A10BD14" ,
                                     "A10BD15" ,
                                     "A10BD16" ,
                                     "A10BD17" ,
                                     "A10BD18" ,
                                     "A10BD20" ;
           rdfs:label "metformin" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitismethotrexate
:methotrexate rdf:type owl:NamedIndividual ,
                       OpenPVSignal:Drug ;
              OpenPVSignal:has_ATC_code "L01BA01" ,
                                        "L04AX03" ;
              rdfs:label "methotrexate" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisminocycline
:minocycline rdf:type owl:NamedIndividual ,
                      OpenPVSignal:Drug ;
             OpenPVSignal:has_ATC_code "A01AB23" ,
                                       "J01AA08" ;
             rdfs:label "minocycline" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisomeprazole
:omeprazole rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Drug ;
            OpenPVSignal:has_ATC_code "A02BC01" ,
                                      "A02BD01" ,
                                      "A02BD05" ;
            rdfs:label "omeprazole" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisonset3
:onset3 rdf:type owl:NamedIndividual ,
                 time:DurationDescription ;
        time:nominalPosition "days" ;
        time:numericPosition 2 ;
        rdfs:label "onset 3" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisonset5
:onset5 rdf:type owl:NamedIndividual ,
                 time:DurationDescription ;
        time:nominalPosition "days" ;
        time:numericPosition 49 ;
        rdfs:label "onset 5" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisonset7
:onset7 rdf:type owl:NamedIndividual ,
                 time:DurationDescription ;
        time:nominalPosition "days" ;
        time:numericPosition 877 ;
        rdfs:label "onset 7" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisonset8
:onset8 rdf:type owl:NamedIndividual ,
                 time:DurationDescription ;
        time:nominalPosition "days" ;
        time:numericPosition 866 ;
        rdfs:label "onset 8" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisonset9
:onset9 rdf:type owl:NamedIndividual ,
                 time:DurationDescription ;
        time:nominalPosition "days" ;
        time:numericPosition 10 ;
        rdfs:label "onset 9" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitispostMarketingUstekinumabReports
:postMarketingUstekinumabReports rdf:type owl:NamedIndividual ,
                                          obo:OAE_0001197 ;
                                 OpenPVSignal:is_supported_by_statistical_entity :HypersensitivityReactionsForUstekinumab ,
                                                                                 <http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitis#rash/urticariaForUstekinumab> ;
                                 OpenPVSignal:refers_to_adverse_effect :anaphylaxis ,
                                                                       :angioedema ;
                                 OpenPVSignal:refers_to_drug :ustekinumab ;
                                 mp:references :Ref.3 ,
                                               :Ref.4 ;
                                 OpenPVSignal:has_content "However, anaphylaxis and angioedema have been reported in association with ustekinumab therapy in post marketing settings.3,4" ;
                                 rdfs:label "post marketing ustekinumab reports" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitispruritus
:pruritus rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Adverse_Effect ;
          OpenPVSignal:has_MedDRA_code 10037087 ;
          OpenPVSignal:has_MedDRA_prefered_term "Pruritus" ;
          rdfs:label "pruritus" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitispsoriasis
:psoriasis rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Adverse_Effect ,
                    OpenPVSignal:Indication ;
           OpenPVSignal:has_MedDRA_code 10037153 ;
           OpenPVSignal:has_MedDRA_prefered_term "Psoriasis" ;
           rdfs:label "psoriasis" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitispsoriasis_and_no_cases_of_serious_hypersensitivity
:psoriasis_and_no_cases_of_serious_hypersensitivity rdf:type owl:NamedIndividual ,
                                                             obo:OAE_0001182 ,
                                                             OpenPVSignal:Clinical_trial_information ;
                                                    mp:references :Ref.7 ,
                                                                  :Ref.8 ,
                                                                  :Ref.9 ;
                                                    OpenPVSignal:has_content "In clinical trials on psoriasis patients, no cases of serious hypersensitivity, e.g. anaphylaxis or serum sickness-like reactions, were observed.7 Also based on the available phase III clinical trials data on short term safety (52 weeks) of ustekinumab in PsA patients, there are no reported incidences of serious hypersensitivity reactions.8,9" ;
                                                    rdfs:label "psoriasis and no cases of serious hypersensitivity" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitispsoriaticArthritis
:psoriaticArthritis rdf:type owl:NamedIndividual ,
                             OpenPVSignal:Adverse_Effect ,
                             OpenPVSignal:Indication ;
                    OpenPVSignal:has_MedDRA_code 10037162 ;
                    OpenPVSignal:has_MedDRA_prefered_term "Psoriatic arthropathy" ;
                    rdfs:label "psoriatic arthritis" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitispvSignal
:pvSignal rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Signal ;
          OpenPVSignal:Free_text_reporting_element :DiscussionAndConclusion ,
                                                   :IntroductionContent ,
                                                   :ReportsInVigibase ,
                                                   :SummaryContent ,
                                                   :Vasculitis ;
          OpenPVSignal:is_supported_by_individual_case_report :Report1 ,
                                                              :Report2 ,
                                                              :Report3 ,
                                                              :Report4 ,
                                                              :Report5 ,
                                                              :Report6 ,
                                                              :Report7 ,
                                                              :Report8 ,
                                                              :Report9 ;
          OpenPVSignal:is_supported_by_statistical_entity :HypersensitivityReactionsForUstekinumab ,
                                                          :IC025ValueForUstekinumabAndVasculitis ,
                                                          :ICValueForUstekinumabAndVasculitis ,
                                                          :dataOnImmunogenicityOfUstekinumab ,
                                                          :incidenceOfPsoriasis ,
                                                          :reportsInVigibase ,
                                                          :reportsWithConcomitantDrugs ,
                                                          :reportsWithCutaneousVasculitis ,
                                                          :reportsWithDechallenge ,
                                                          :reportsWithLeukocytoclasticVasculitis ,
                                                          :reportsWithNegativeDechallenge ,
                                                          :reportsWithNoRecoveryAsOutcome ,
                                                          :reportsWithRecoveryAsOutcome ,
                                                          :reportsWithUnknownAsOutcome ,
                                                          :reportsWithUstekinumabAsTheSingleSuspectDrug ,
                                                          :reports_from_Canada ,
                                                          :reports_from_Greece ,
                                                          :reports_from_Spain ,
                                                          :reports_from_UK ,
                                                          :reports_from_USA ,
                                                          :reports_from_heatlh_care_professional ,
                                                          :reports_from_literature ,
                                                          :reports_with_dechallenge_and_unknown ,
                                                          <http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitis#rash/urticariaForUstekinumab> ;
          OpenPVSignal:refers_to_adverse_effect :vasculitis ;
          OpenPVSignal:refers_to_drug :ustekinumab ;
          OpenPVSignal:refers_to_primary_suspect_drug :ustekinumab ;
          mp:supportedByData :SignalOriginality ,
                             :TNFa_inhibitors_and_vasculitis ,
                             :postMarketingUstekinumabReports ,
                             :psoriasis_and_no_cases_of_serious_hypersensitivity ,
                             :serum_sickness_records ;
          OpenPVSignal:initially_identified_on "01/07/2014" ;
          rdfs:label "pv signal" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisramipril
:ramipril rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Drug ;
          OpenPVSignal:has_ATC_code "C09AA05" ,
                                    "C09BA05" ,
                                    "C09BB05" ,
                                    "C09BB07" ,
                                    "C10BX04" ,
                                    "C10BX06" ;
          rdfs:label "ramipril" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisrash
:rash rdf:type owl:NamedIndividual ,
               OpenPVSignal:Adverse_Effect ;
      OpenPVSignal:has_MedDRA_code 10037844 ;
      OpenPVSignal:has_MedDRA_prefered_term "Rash" ;
      rdfs:label "rash" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisreportsInVigibase
:reportsInVigibase rdf:type owl:NamedIndividual ,
                            OpenPVSignal:Reports_group ;
                   OpenPVSignal:concerns_indication_for_use :psoriasis ;
                   OpenPVSignal:refers_to_adverse_effect :vasculitis ;
                   OpenPVSignal:refers_to_drug :ustekinumab ;
                   OpenPVSignal:has_count 8 ;
                   OpenPVSignal:has_count_of_men 1 ;
                   OpenPVSignal:has_count_of_women 7 ;
                   OpenPVSignal:has_max_age "64.0"^^xsd:float ;
                   OpenPVSignal:has_min_age "29.0"^^xsd:float ;
                   OpenPVSignal:refers_to_database "WHO Vigibase" ;
                   rdfs:label "overall reports in vigibase" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisreportsWithConcomitantDrugs
:reportsWithConcomitantDrugs rdf:type owl:NamedIndividual ,
                                      OpenPVSignal:Reports_group ;
                             OpenPVSignal:is_subgroup_of :reportsWithUstekinumabAsTheSingleSuspectDrug ;
                             OpenPVSignal:has_count 4 ;
                             OpenPVSignal:refers_to_database "WHO Vigibase" ;
                             rdfs:label "reports with concomitant drugs" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisreportsWithCutaneousVasculitis
:reportsWithCutaneousVasculitis rdf:type owl:NamedIndividual ,
                                         OpenPVSignal:Reports_group ;
                                OpenPVSignal:is_subgroup_of :reportsInVigibase ;
                                OpenPVSignal:refers_to_adverse_effect :cutaneousVasculitis ;
                                OpenPVSignal:has_count 2 ;
                                OpenPVSignal:refers_to_database "WHO Vigibase" ;
                                rdfs:label "reports with cutaneous vasculitis" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisreportsWithDechallenge
:reportsWithDechallenge rdf:type owl:NamedIndividual ,
                                 OpenPVSignal:Reports_group ;
                        OpenPVSignal:is_subgroup_of :reportsWithRecoveryAsOutcome ;
                        OpenPVSignal:has_count 2 ;
                        OpenPVSignal:refers_to_database "WHO Vigibase" ;
                        OpenPVSignal:refers_to_dechallenge_outcome "positive - condition not applied" ;
                        rdfs:label "reports with positive dechallenge" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisreportsWithLeukocytoclasticVasculitis
:reportsWithLeukocytoclasticVasculitis rdf:type owl:NamedIndividual ,
                                                OpenPVSignal:Reports_group ;
                                       OpenPVSignal:is_subgroup_of :reportsInVigibase ;
                                       OpenPVSignal:refers_to_adverse_effect :leukocytoclastic_vasculitis ;
                                       OpenPVSignal:has_count 2 ;
                                       OpenPVSignal:refers_to_database "WHO Vigibase" ;
                                       rdfs:label "reports with leukocytoclastic vasculitis" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisreportsWithNegativeDechallenge
:reportsWithNegativeDechallenge rdf:type owl:NamedIndividual ,
                                         OpenPVSignal:Reports_group ;
                                OpenPVSignal:is_subgroup_of :reportsInVigibase ;
                                OpenPVSignal:has_count 2 ;
                                OpenPVSignal:refers_to_database "WHO Vigibase" ;
                                OpenPVSignal:refers_to_rechallenge_outcome "negative rechallenge - condition not appeared" ;
                                rdfs:label "reports with negative rechallenge" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisreportsWithNoRecoveryAsOutcome
:reportsWithNoRecoveryAsOutcome rdf:type owl:NamedIndividual ,
                                         OpenPVSignal:Reports_group ;
                                OpenPVSignal:is_subgroup_of :reportsInVigibase ;
                                OpenPVSignal:has_count 1 ;
                                OpenPVSignal:refers_to_database "WHO Vigibase" ;
                                OpenPVSignal:refers_to_outcome_after_action "no recovery" ;
                                rdfs:label "reports with no recovery as outcome" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisreportsWithRecoveryAsOutcome
:reportsWithRecoveryAsOutcome rdf:type owl:NamedIndividual ,
                                       OpenPVSignal:Reports_group ;
                              OpenPVSignal:is_subgroup_of :reportsInVigibase ;
                              OpenPVSignal:has_count 4 ;
                              OpenPVSignal:refers_to_database "WHO Vigibase" ;
                              OpenPVSignal:refers_to_outcome_after_action "recovery with no further information" ;
                              rdfs:label "reports with recovery as outcome" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisreportsWithUnknownAsOutcome
:reportsWithUnknownAsOutcome rdf:type owl:NamedIndividual ,
                                      OpenPVSignal:Reports_group ;
                             OpenPVSignal:is_subgroup_of :reportsInVigibase ;
                             OpenPVSignal:has_count 1 ;
                             OpenPVSignal:refers_to_database "WHO Vigibase" ;
                             OpenPVSignal:refers_to_outcome_after_action "unknown" ;
                             rdfs:label "reports with unknown as outcome" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisreportsWithUstekinumabAsTheSingleSuspectDrug
:reportsWithUstekinumabAsTheSingleSuspectDrug rdf:type owl:NamedIndividual ,
                                                       OpenPVSignal:Reports_group ;
                                              OpenPVSignal:is_subgroup_of :reportsInVigibase ;
                                              OpenPVSignal:refers_to_primary_suspect_drug :ustekinumab ;
                                              OpenPVSignal:has_count 6 ;
                                              OpenPVSignal:refers_to_database "WHO Vigibase" ;
                                              rdfs:label "reports with ustekinumab as the single suspect drug" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisreports_from_Canada
:reports_from_Canada rdf:type owl:NamedIndividual ,
                              OpenPVSignal:Reports_group ;
                     OpenPVSignal:is_subgroup_of :reportsInVigibase ;
                     OpenPVSignal:has_count 2 ;
                     OpenPVSignal:refers_to_country "http://dbpedia.org/resource/Canada" ;
                     OpenPVSignal:refers_to_database "WHO Vigibase" ;
                     rdfs:label "reports from Canada" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisreports_from_Greece
:reports_from_Greece rdf:type owl:NamedIndividual ,
                              OpenPVSignal:Reports_group ;
                     OpenPVSignal:is_subgroup_of :reportsInVigibase ;
                     OpenPVSignal:has_count 1 ;
                     OpenPVSignal:refers_to_country "http://dbpedia.org/resource/Greece" ;
                     OpenPVSignal:refers_to_database "WHO Vigibase" ;
                     rdfs:label "reports from Greece" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisreports_from_Spain
:reports_from_Spain rdf:type owl:NamedIndividual ,
                             OpenPVSignal:Reports_group ;
                    OpenPVSignal:is_subgroup_of :reportsInVigibase ;
                    OpenPVSignal:has_count 1 ;
                    OpenPVSignal:refers_to_country "http://dbpedia.org/resource/Spain" ;
                    OpenPVSignal:refers_to_database "WHO Vigibase" ;
                    rdfs:label "reports from Spain" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisreports_from_UK
:reports_from_UK rdf:type owl:NamedIndividual ,
                          OpenPVSignal:Reports_group ;
                 OpenPVSignal:is_subgroup_of :reportsInVigibase ;
                 OpenPVSignal:has_count 2 ;
                 OpenPVSignal:refers_to_country "http://dbpedia.org/resource/United_Kingdom" ;
                 OpenPVSignal:refers_to_database "WHO Vigibase" ;
                 rdfs:label "reports from UK" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisreports_from_USA
:reports_from_USA rdf:type owl:NamedIndividual ,
                           OpenPVSignal:Reports_group ;
                  OpenPVSignal:is_subgroup_of :reportsInVigibase ;
                  OpenPVSignal:has_count 2 ;
                  OpenPVSignal:refers_to_country "http://dbpedia.org/resource/United_States" ;
                  OpenPVSignal:refers_to_database "WHO Vigibase" ;
                  rdfs:label "reports from USA" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisreports_from_heatlh_care_professional
:reports_from_heatlh_care_professional rdf:type owl:NamedIndividual ,
                                                OpenPVSignal:Reports_group ;
                                       OpenPVSignal:is_subgroup_of :reportsInVigibase ;
                                       OpenPVSignal:has_count 6 ;
                                       OpenPVSignal:has_reporter_type "health care professional" ;
                                       OpenPVSignal:refers_to_database "WHO Vigibase" ;
                                       rdfs:label "reports from heatlh care professional" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisreports_from_literature
:reports_from_literature rdf:type owl:NamedIndividual ,
                                  OpenPVSignal:Reports_group ;
                         OpenPVSignal:is_subgroup_of :reportsInVigibase ;
                         OpenPVSignal:has_count 1 ;
                         OpenPVSignal:has_reporter_type "study" ;
                         OpenPVSignal:refers_to_database "WHO Vigibase" ;
                         rdfs:label "reports from literature" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisreports_with_dechallenge_and_unknown
:reports_with_dechallenge_and_unknown rdf:type owl:NamedIndividual ,
                                               OpenPVSignal:Reports_group ;
                                      OpenPVSignal:is_subgroup_of :reportsInVigibase ;
                                      OpenPVSignal:has_count 1 ;
                                      OpenPVSignal:refers_to_database "WHO Vigibase" ;
                                      OpenPVSignal:refers_to_dechallenge_outcome "unknown" ;
                                      rdfs:label "reports with dechallenge and unknown" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisrespiratoryDepression
:respiratoryDepression rdf:type owl:NamedIndividual ,
                                OpenPVSignal:Adverse_Effect ;
                       OpenPVSignal:has_MedDRA_code 10038678 ;
                       OpenPVSignal:has_MedDRA_prefered_term "Respiratory depression" ;
                       rdfs:label "respiratory depression" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitissalbutamol
:salbutamol rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Drug ;
            OpenPVSignal:has_ATC_code "R03AC02" ,
                                      "R03AK04" ,
                                      "R03AL02" ,
                                      "R03CC02" ;
            rdfs:label "salbutamol" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisserumSickness
:serumSickness rdf:type owl:NamedIndividual ,
                        OpenPVSignal:Adverse_Effect ;
               OpenPVSignal:has_MedDRA_code 10040400 ;
               OpenPVSignal:has_MedDRA_prefered_term "Serum sickness" ;
               rdfs:label "serum sickness" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisserum_sickness_records
:serum_sickness_records rdf:type owl:NamedIndividual ,
                                 OpenPVSignal:Warning_Information ;
                        OpenPVSignal:refers_to_drug :ustekinumab ;
                        mp:references :Ref.14 ,
                                      :Ref.7 ,
                                      :Ref.8 ;
                        OpenPVSignal:has_content "Another immunologically related reaction of interest is serum sickness, having no records of reported incidences during clinical trials with ustekinumab in psoriasis or in PsA patients.7,8,14" ;
                        rdfs:label "serum sickness records" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitissomnolence
:somnolence rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Adverse_Effect ;
            OpenPVSignal:has_MedDRA_code 10041349 ;
            OpenPVSignal:has_MedDRA_prefered_term "Somnolence" ;
            rdfs:label "somnolence" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitistachycardia
:tachycardia rdf:type owl:NamedIndividual ,
                      OpenPVSignal:Adverse_Effect ;
             OpenPVSignal:has_MedDRA_code 10043071 ;
             OpenPVSignal:has_MedDRA_prefered_term "Tachycardia" ;
             rdfs:label "tachycardia" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisurticaria
:urticaria rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Adverse_Effect ;
           OpenPVSignal:has_MedDRA_code 10046735 ;
           OpenPVSignal:has_MedDRA_prefered_term "Urticaria" ;
           rdfs:label "urticaria" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisusage_of_ustekinumab
:usage_of_ustekinumab rdf:type owl:NamedIndividual ,
                               OpenPVSignal:Drug_Usage ;
                      OpenPVSignal:concerns_indication_for_use :psoriasis ,
                                                               :psoriaticArthritis ;
                      OpenPVSignal:refers_to_drug :ustekinumab ;
                      rdfs:label "usage of ustekinumab" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisustekinumab
:ustekinumab rdf:type owl:NamedIndividual ,
                      OpenPVSignal:Drug ;
             OpenPVSignal:has_mechanism :MechanismOfUstekinumab ;
             OpenPVSignal:has_ATC_code "L04AC05" ;
             rdfs:label "ustekinumab" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisvasculitis
:vasculitis rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Adverse_Effect ;
            OpenPVSignal:has_MedDRA_code 10047115 ;
            OpenPVSignal:has_MedDRA_prefered_term "Vasculitis" ;
            rdfs:label "vasculitis" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitisvenlafaxine
:venlafaxine rdf:type owl:NamedIndividual ,
                      OpenPVSignal:Drug ;
             OpenPVSignal:has_ATC_code "N06AX16" ;
             rdfs:label "venlafaxine" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitis#fluticasonepropionate/salmeterolXinafoate
<http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitis#fluticasonepropionate/salmeterolXinafoate> rdf:type owl:NamedIndividual ,
                                                                                                                        OpenPVSignal:Drug ;
                                                                                                               OpenPVSignal:has_ATC_code "R03AK06" ;
                                                                                                               rdfs:label "fluticasone propionate/salmeterol xinafoate" .


###  http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitis#rash/urticariaForUstekinumab
<http://purl.org/OpenPVSignal/Signals/2014_3_ustekinumab_vasculitis#rash/urticariaForUstekinumab> rdf:type owl:NamedIndividual ,
                                                                                                           OpenPVSignal:Statistical_Entity ;
                                                                                                  OpenPVSignal:refers_to_adverse_effect :rash ,
                                                                                                                                        :urticaria ;
                                                                                                  mp:references :Ref.3 ;
                                                                                                  OpenPVSignal:has_content "Rash and urticaria have been documented to occur in <1% of patients during the controlled periods of clinical studies and are labelled as uncommon in the EU.3" ;
                                                                                                  rdfs:label "rash/urticaria for ustekinumab" .


###  Generated by the OWL API (version 4.5.9.2019-02-01T07:24:44Z) https://github.com/owlcs/owlapi
